Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor by Rice, Lisa et al.
Identiﬁcation and functional analysis of SKA2 interaction with
the glucocorticoid receptor
Lisa Rice
1,2, Charlotte E Waters
1, Jennifer Eccles
1, Helen Garside
1, Paula Sommer
1, Paul Kay
1,
Fiona H Blackhall
1, Leo Zeef
2, Brian Telfer
3, Ian Stratford
3, Rob Clarke
1, Dave Singh
1,
Adam Stevens
1, Anne White
1,2 and David W Ray
1
1Faculty of Medical and Human Sciences, School of Medicine,
2Faculty of Life Sciences and
3Faculty of Medical and Human Sciences, School of Pharmacy,
University of Manchester, Manchester M13 9PT, UK
(Correspondence should be addressed to D Ray, Centre for Molecular Medicine, and Endocrine Sciences Research Group, Faculty of Medical and Human
Sciences, University of Manchester, Stopford Building, Manchester M13 9PT, UK; Email: david.w.ray@manchester.ac.uk)
Abstract
Glucocorticoid (GC) receptors (GRs) have profound anti-
survival effects on human small cell lung cancer (SCLC). To
explore the basis of these effects, protein partners for GRs were
sought using a yeast two-hybrid screen. We discovered a novel
gene, FAM33A, subsequently identiﬁed as a SKA1 partner and
involved in mitosis, and so renamed Ska2. We produced an anti-
peptide antibody that speciﬁcally recognized full-length human
SKA2 to measure expression in human cell lines and tissues.
Therewasawidevariationinexpressionacrossmultiplecelllines,
but none was detected in the liver cell line HepG2. A xenograft
model of human SCLC had intense staining and archival tissue
revealed SKA2 in several human lung and breast tumours. SKA2
was found in the cytoplasm, where it co-localized with GR, but
nuclear expression of SKA2 was seen in breast tumours. SKA2
overexpression increased GC transactivation in HepG2 cells
while SKA2 knockdown in A549 human lung epithelial cells
decreased transactivation and prevented dexamethasone inhi-
bition of proliferation. GC treatment decreased SKA2 protein
levels in A549 cells, as did Staurosporine, phorbol ester and
trichostatin A; all agents that inhibit cell proliferation. Over-
expression of SKA2 potentiated the proliferative response to
IGF-I exposure, and knockdown with shRNA caused cells to
arrest in mitosis. SKA2 has recently been identiﬁed in HeLa S3
c e l l sa sp a rto fac o m p l e x ,w h i c hi sc ri t i c a lf o rs p i n d l ec h e c k p o i n t
silencing and exit from mitosis. Our new data show involvement
in cell proliferation and GC signalling, with implications for
understanding how GCs impact on cell fate.
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Introduction
Glucocorticoids (GC) act through the GC receptor (GR), a
member of the nuclear receptor superfamily of ligand-
regulated transcription factors (Hollenberg et al.1 9 8 5 ,
Weinberger et al. 1985, 1987, Perlmann & Evans 1997,
Margolis et al. 2005, Bookout et al. 2006). On activation, the
GR is capableof both upregulating and downregulating target
gene expression (Ray et al. 1999). The ﬁnal functional effect
of activated GR in a given cell is critically determined by its
interactions with a spectrum of co-modulator proteins
(Lonard et al. 2004, O’Malley 2004, Wu et al. 2005). Several
canonical nuclear receptor interaction motifs are well
recognized, including LxxLL and LIM domains (Cheskis
et al. 2003, Kassel et al. 2004), but in addition, other
interacting partners do not have deﬁned peptide motifs,
e.g. RelA (Nissen & Yamamoto 2000, Garside et al. 2004).
While the co-modulator families primarily alter the
amplitude of the GR effect, e.g. steroid receptor coactivator
1; (SRC1; Stevens et al. 2003), other GR-interacting proteins
are responsible for mediating GR action, e.g. activator
protein 1 (AP-1; Gottlicher et al. 1998).
GCs arewidely used in the initial treatment of patientswith
lung cancer, primarily for their anti-emetic and anti-
inﬂammatory effects, but direct anti-tumour action has also
been proposed (Sommer et al. 2007). They have profound
inhibitoryeffectsoncellcycleprogressionandcellproliferation
in human lung cancer cell lines (Hofmann et al. 1995). GCs,
such as dexamethasone (Dex), have also been shown to have
anti-tumourigenic effects in mouse models of lung cancer
(Witschi et al. 2005). The mode of action in this model is
unclear but it is thought that GCs affect cell differentiation.
Alternatively,GCsmaybeacting inthe lungcancer modelsby
inhibiting cell proliferation, given their effects in human lung
cancercells(Hofmannetal.1995).Wehavecharacterizedsmall
cell lung carcinoma (SCLC) cells that are deﬁcient in GR
expression and resistant to GC action (Ray et al. 1994,
Hofmann et al. 1995, Sommer et al. 2007). Importantly,
overexpression of the GR in these cells powerfully induced
apoptosis (Sommer et al. 2007), suggesting that acquisition of
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(Sommeretal.2007).Thus,theGRisapotentiallyinformative
node for novel pathogenic mechanisms in lung cancer.
Our aim was to ﬁnd novel GR-interacting proteins
expressed in the well-characterized SCLC cells, which
could provide new insights into the cellular mechanisms
associated with their proliferative potential. Using a yeast
two-hybrid screen we identiﬁed a speciﬁc interaction
between GR and FAM33A, which has recently been
identiﬁed as SKA2, a conserved protein involved in the
kinetochore complex (Hanisch et al. 2006). Depletion of
SKA2 by small interfering RNAs causes the cells to be
suspended in a metaphase-like state. This delays the exit from
mitosis and the onset of anaphase. From this, the authors
propose that the SKA complex is required for stabilizing
kinetochore-microtubule attachments and/or checkpoint
silencing.
The studies presented hereon the identiﬁcation of SKA2 in
human tumour cell lines, its interaction with the GR and the
impact of depletion of SKA2 on apoptotic- and proliferation-
associated genes suggest SKA2 may play a role in regulation of
lung cancer cell proliferation.
Materials and Methods
Compounds
Dex, phorbol 12-myristate 13-acetate, Forskolin, trichostatin
A (TSA) and insulin-like growth factor-I (IGF-I) were from
Sigma–Aldrich; mifepristone (RU486) was from Afﬁnity
Bioreagents; Staurosporine was purchased from Calbiochem
(Darmstadt, Germany).
Cell culture
The human lung epithelial carcinoma cell line, A549, the
human liver carcinoma cell line, HepG2, 3T3L1 adipocyte
cells and the human embryonic kidney cell line, HEK293,
were obtained from ECACC (Porton Down, UK). A549,
HEK293 and 3T3-L1 cells were maintained in Dulbecco’s
modiﬁedEagle’smedium(DMEM)with10%foetalcalfserum
(FCS). HepG2 liver carcinoma cells were maintained in
Minimum Essential Medium (Eagle) containing Earl’s salts
supplemented with 10% FCS and 1% non-essential amino
acids. CORL103, CORL24 and DMS79 cells were derived
from histologically conﬁrmed bronchiogenic SCLC
(Pettengill et al. 1980, Baillie-Johnson et al. 1985). SCLC
cells were cultured in RPMI 1640 medium (Sigma–Aldrich),
supplemented with 2.5% FCS and 10 mM HEPES (Ray et al.
1994, 1996a). CEM-7A cells were obtained from Dr Ged
Brady (EpiStem Ltd, Manchester, UK) and maintained in
RPMI 1640 medium supplemented with Glutamax (Invi-
trogen) and 10% FCS (Alourﬁ et al. 2005). Rat-1 cells were
obtainedfromATCCandmaintainedinhighglucoseDMEM
supplemented with Glutamax (Invitrogen) and 10% FCS.
AtT20 cellswereobtained from ECCACand werecultured as
described (Ray et al. 1996b).
All cells were cultured in normal growth medium
supplemented with 10% charcoal dextran-stripped FCS
(HyClone, Logan, UT, USA) before treatment with Dex.
Yeast two-hybrid screen
The yeast two-hybrid screen has been reported before
(Garside et al. 2006).
DNA constructs
The pcDNA3GR plasmid has been previously described (Ray
et al. 1999). The TAT3-luc plasmid was a kind gift from Prof.
Keith Yamamoto and Dr Jorge Iniguez-Lluhi (Department of
Cellular and Molecular Pharmacology, University of Cali-
fornia, San Francisco) (Iniguez-Lluhi et al. 1997). The cMyc-
SKA2 construct contained the open reading frame inserted
into the N-terminal cMyc tagged vector cytomegalovirus
(CMV)-Tag3B (Stratagene). AGST-SKA2 fusion plasmid was
made by inserting SKA2 cDNA into the pGEX-5X-1 vector
(Amersham Pharmacia Biotech).
SKA2 shRNAvectors were made using the vector pSUPER
(Oligoengine, Seattle, WA, USA). Sense and antisense oligonu-
cleotide sequences were made (MWG Biotech AG, London,
UK). Knockdown sequence: 50-GATCCCCGGCTGGAA-
TATGAAATCAATTCAAGAGATTGATTTCATATTCCA-
GCCTTTTTCGAAA-30 and scrambled bp control: 50-
GATCCCCTTCTCCGAACGTGTCACGTTTCAAGAG-
AACGTGACACGTTCGGAGAATTTTTCGAAA-30.
BglII and HindIII restriction sites added to the sequences
were used for subsequent ligation into pSUPER. The
oligonucleotides were annealed by adding 3 mg of each into
48 ml annealing buffer (100 mM sodium chloride, 50 mM
HEPES (pH 7.4)). The mixture was then incubated at 90 8C
for4 min,followedby70 8Cfor10 min.Themixturewasthen
slowly cooled to 10 8C. The shRNA sequences were then
ligated into pSUPER using T4 DNA ligase (Roche).
Interaction between Ska2 and GR in vitro
GST and GST-SKA2 were expressed in Escherichia coli strain
DH5a (Promega Corp.) and were puriﬁed as described
(Stevens et al. 2003).
Western blotting
Cells were lysed using 1! RIPA buffer (100 mM Tris base,
150 mM NaCl, 1% Igepal, 2.5% sodium deoxycholate, 1 mM
EDTA) and tissues lysed using a modiﬁed RIPA buffer (50 mM
Tris–HCl, 150 mM NaCl, 1% Triton X-100, 1% sodium
deo xycholate,1mMEDT A,0.1%SDS).Bothbufferscontained
proteaseinhibitors(Complete,RocheMolecularBiochemicals).
CellandtissueextractswereanalysedbySDS-PAGEandwestern
blotting using the following primary antibodies: 1:1000 SKA2
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sequence) or 1:2000 mouse monoclonal a-tubulin (DM1A,
Sigma–AldrichLtd).Thespeciﬁcityofthe14 kDabanddetected
using SKA2 antibody (see above) was conﬁrmed using SKA2-
speciﬁc blocking peptides, antibody was incubated with a
ﬁvefold excess, by weight, of the immunogenic peptide
overnight at 4 8C in 1% milk blocking buffer.
Immunoﬂuorescence
HEK293 cells infected with a GR-eYFP-expressing retro-
virus and A549 cells were grown on coverslips and treated
with either DMSO (vehicle), Dex (100 nM) or RU486
(100 nM) for 1 h. The cells were washed with 1! PBS and
ﬁxed with 4% paraformaldehyde. Human lung tissue was
obtained from the North West Lung Centre, Medicines
Evaluation Unit, Wythenshawe Hospital, Manchester, UK.
After ﬁxation with 4% paraformaldehyde, tissue sections and
cells were permeabilized with TD buffer (10 mM Tris–HCl
(pH 8.0) and 50 mM NaCl) and blocked with TD buffer
containing 1% BSA and 0.2% Triton X-100. A 1:400 dilution
of SKA2 anti-peptide antibody (see above) in washing buffer
(TD buffer plus 1% BSA and 0.05% Triton X-100) was added
for 2 h at room temperature. Images were taken using a Bio-
Rad MRC1024 confocal scanning Microscope, as previously
described (Garside et al. 2006).
Quantiﬁcation of nuclear/cytoplasmic staining
HEK293cellsfromtriplicateslidesofthreeseparateexperiments
were scored for nuclear and cytoplasmic localization of both
Texas Red-conjugated proteins and eYFP-tagged proteins.
Treated and untreated cells were assigned ‘predominantly
cytoplasmic’ (C) or ‘predominantly nuclear’ (N) for both
SKA2 and GR-eYFP by a masked observer. These numbers
were expressed as a percentage of the total cell number.
Generation of stable cell lines
The cMyc-SKA2 plasmid DNAwas linearized and transfected
usingFuGENE6(Roche).Cellswereincubatedwith1 mg/ml
G418 sulphate. After 2 weeks discrete colonies formed, which
were cloned and screened for gene expression by western blot.
To create stable cell lines expressing shRNA, cells were
co-transfected using FuGENE 6 (Roche) with the appropriate
pSUPER vector and the vector pcDNA3 (to confer G418
resistancetothecell).After48 htransfection,thegrowthmedium
ofthecellswassupplementedwith1 mg/mlG418(Calbiochem).
Colonies were selected and expanded under G418 selection.
Reporter gene studies
Cells were transfected with the TAT3-luc reporter gene and
analysed as previously described (Stevens et al. 2003, Garside
et al. 2004, 2006).
Proliferation assays
Cells were seeded in 96-well plates and treated as indicated.
Cell number was estimated using the MTS reagent (American
Tissue Culture Collection) or measured by haemocytometer.
Immunohistochemistry of human lung cancer
Human SCLC xenografts were obtained by innoculating 10
8
DMS 79 cells with Matrigel (1:1) subcutaneously in the ﬂank
of athymic, nude mice. In addition, a panel of human lung
cancer and malignant mesotheliomas from biopsy tissue
surplus to requirements for clinical diagnosis was obtained
from patients at Manchester Royal Inﬁrmary and Wythen-
shawe Hospital, who had placed no restriction on the use of
surplus tissue when consented for biopsy or resection of
tumour. At least six separate sections were analysed for each
tumour type. SKA2 staining was quantitated in triplicate
sections of a panel of lung carcinomas using a colour card
(0–3 for intensity) compared against a ‘no primary’ control
by a masked observer. Data were averaged across the
triplicates and expressed as intensity from 0 to 3 for each
type of carcinoma.
Staining of mitotic cells
Cells were grown overnight on coverslips and mounted in
40,6-diamidino-2-phenylindole-containing mounting
medium (Vectashield, Vector Laboratories Ltd, Peterborough,
UK). Quantiﬁcation of mitotic ﬁgures was performed using
ﬂuorescent microscopy (excitation and emission at 360 and
460 nm respectively), a ﬁeld of 100 cells was counted and the
percentage of cells undergoing mitosis was calculated.
Breast array
The human breast tissue array has been described previously
(Zhu et al. 2006). Detection of FAM33A expression followed
the standard immunoperoxidase approach. Analysis was done
by a masked observer and statistical comparison by c
2-test.
RNAi
Short interfering siRNAs speciﬁc to SKA2 were custom
designed using the HiPerformance algorithm (Novartis
Pharmaceuticals) and synthesized (Qiagen Ltd). Sequences
are available on request.
Microarray and data analysis
Labelled cDNA was hybridized to HG-U133 PLUS2
oligonucleotide arrays (Affymetrix, Santa Clara, CA, USA).
Technical quality control of the arrays was done to check for
outliers using dChip software (Li & Wong 2001). Normal-
ization and expression analysis used robust multiple array
average (RMA;Bolstadetal.2003).Sinceoff-targeteffectscan
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were used. Each experiment was done in duplicate. Statistical
analysis was performed by comparing non-silencing control
with the combined siRNA samples group with limma (Smyth
2004). False discovery rate correction was performed with
QVALUE (Storey et al. 2004). Post-analysis was performed
using the MAPPFinder Gene Ontology tool of GenMapp 2.0
software, San Francisco, CA, USA (Doniger et al. 2003),
DAVID Bioinformatics Resources 2006 and MetaCore
software(GeneGo,Inc.,StJoseph,MI,USA).Themicroarray
data were submitted in a Minimum Information About a
Microarray Experiment-compliant format to the ArrayEx-
press database (http://www.ebi.ac.uk/arrayexpress/) and an
accession number was assigned (E-MEXP-265).
siRNA sequences
The duplex sequences were as follows: siRNA #1 sense
strand r(CCC ACA GAA CCU AAA GUA A)dTCdT and
antisense strand r(UUA CUU UAG GUU CUG UGG
G)dAdG; siRNA #3 sense strand r(GGC UGG AAU AUG
AAAUCA A)dTdTand antisense strand r(UUG AUU UCA
UAU UCC AGC C)dTdG; siRNA #4 sense strand r(CGA
UUU AAA UAU AUG UAC A)dTdT and antisense strand
r(UGU ACA UAU AUU UAA AUC G)dTdT.
A commercially available non-silencing control siRNA
(Qiagen Ltd) was transfected to control for off-target effects.
The sequence for the sense strand of this duplex was UUC
UCC GAA CGU GUC ACG UdT dT and the antisense
strand, ACG UGA CAC GUU CGG AGA AdT dT.
Figure 1 SKA2 interacts with the GR in yeast and in vitro. (a) Yeast are transformed with reporter, GR ‘bait’,
and library clone R59 (encoding SKA2). A single colony was selected from the stock plate and used to create
liquid cultures of yeast cells. These were incubated, in triplicate, for 3 h with either vehicle (no ligand, NL),
50 mM dexamethasone (Dex) or 50 mM RU486. The cells were then lysed and incubated with CPRG
substrate. Background activity in these assays was !1. (b) Evolutionary sequence comparison between
human and both rat and mouse SKA2. Non-identical amino acids are highlighted. (c) Autoradiograph of a
GST ‘pull down’ in which [
35S]GR was incubated with GST-SKA2 or GSTalone in the presence or absence of
dexamethasone (50 mM) or RU486 (50 mM). The GSTwas pulled down and the resulting complexes resolved
by SDS-PAGE. The
35S-labeled GR bound to the GST fusion protein was visualized by phosphoimaging.
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All additional statistical analysis was carried out using SPSS
(Chicago, IL, USA) for Windows version 13.0. Speciﬁc tests
are described in the ﬁgure legends.
Results
Identiﬁcation of SKA2 as a GR-interacting protein
We identiﬁedSKA2as interactingwiththeC-terminaldomain
of the GR (amino acids 525–777) in a yeast two-hybrid library
Figure 2 SKA2 is a 14 kDa protein expressed in SCLC and non-
SCLC cell lines. (a) Western blot showing SKA2 protein expression
using novel anti-peptide antibody. The SKA2 immunogenic peptide
(lane 1), endogenous SKA2 in A549 cell lysate (lane 2), and
recombinant bacterially expressed GST-SKA2 (lane 3) were
detected as bands of 8, 14 and 42 kDa, as predicted. Peptide-
blocked antibody controls are also shown, as indicated. (b) Western
blot showing SKA2 expressionin cell lines and tissues. A549 human
non-SCLC cells, normal human lung tissue, DMS79 human SCLC
cells, CORL24 human SCLC cells, HepG2 human liver carcinoma
cells, mouse liver tissue, 3T3L1 mouse ﬁbroblast cells, HEK293
human embryonic kidney cells, CEM-7A human T-lymphoblast
cells, Rat-1 rat ﬁbroblast cells, primary human skin ﬁbroblast cells,
AtT20 mouse pituitary cells, COS7 transformed monkey kidney
ﬁbroblast cells and GH3 rat pituitary cells. (c) Western blot showing
SKA2 expression in human breast cancer cell lines MCF-7,
MCF-10A and MDA-MB231, by comparison with A549 and HeLa
cells. (d) SKA2 protein expression in A549 and HEK293 cells
transfected with empty expression vector (control) and with
cmyc-SKA2. Endogenous SKA2 is a 14 kDa protein and the
exogenous cMyc-SKA2 is an 18 kDa protein.
Figure3 Expressionof SKA2 in lung cancer. (a) Immunoﬂuoresence
analysisof SKA2 in A549cells underbasal and treatmentconditions
as indicated. (b) Immunoperoxidase staining of SKA2 in human
SCLC xenografts in athymic mice and primary human lung
adenocarcinoma. Antibody controls (antibody blocked with
peptide and no primary) are presented, as indicated. Graph shows
small-scale pilot analysis of SKA2 expression in six primary human
lung cancers. At least eight sections from each tumour were scored
by a masked observer against a colour card (0–3 for intensity).
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interaction between GR and SKA2 was conﬁrmed in
re-transformed yeast cells and found to be constitutive but also
seen in the presence of Dex and RU486 (Fig. 1a).
SKA2 is encoded by an 831 nucleotide cDNA sequence,
which derives from a four exon gene located on human
chromosome 17q 23.2 and is highly conserved (Fig. 1b).
There were no indications of protein function from its amino
acid sequence, and no homology with known nuclear
receptor co-modulators.
To conﬁrm a direct interaction between the GR and
SKA2, we used a GST pull-down approach (Stevens et al.
2003). There was a clear interaction between the two
proteins, but little difference was seen in the presence of either
Dex or RU486 (Fig. 1c), as predicted from the yeast studies.
Development of an antibody and analysis of endogenous SKA2
expression
We raised a speciﬁc rabbit antibody to human SKA2 (Fig. 2a).
SKA2 proteinwas detected inbothhuman SCLC andNSCLC
Figure 5 SKA2 co-localizes with GR and moves to the nucleus in
Dex-treated cells. (a) Immunoﬂuorescence of HEK293 cells stably
expressing GR-eYFP, which were treated with vehicle, Dex
(100 nM) or RU486 (100 nM) as indicated, for 1 h before ﬁxation.
The cells were stained for SKA2 using the anti-peptide antibody,
with and without peptide-blocking and a Texas Red-conjugated
secondary antibody. (b) Quantiﬁcation of SKA2 and GR-EYFP
cytoplasmic and nuclear distribution. Cells expressing the GR-eYFP
were selected for analysis. A total of 46 untreated cells and 101
treated cells from three separate experiments were assigned
‘predominantly cytoplasmic’ (C) or ‘predominantly nuclear’ (N) for
both SKA2 and GR-EYFP by a masked observer. Statistical analysis
used ANOVA followed by Tukey–Kramer post hoc test,
***P!0.001.
Figure 4 ExpressionofSKA2innormalhumanlungtissueandnormal
and tumour sectionsfroma breasttissuearray. (a) Immunoperoxidase
stainingofSKA2innormalhumanlungat(iandiv)lowpower,(iiand
v)highpowerand (iiiandvi) peptide adsorbedcontrols. Expressionis
seeninepithelium(Ep),alveolarstructures(Al)andlymphoidfollicles
(Ly). (b) Immunostaining for SKA2 showed cytoplasmic staining with
nuclearexclusionpredominantlyinnormaltissue.Staininginboththe
nucleus and cytoplasm was evident in many tumour samples. The
peptide adsorbed control is shown.
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human liver cell line HepG2 (Fig. 2b). Further immunoblot
analysis revealed SKA2 expression in several breast cancer cell
lines and in HeLa cells (Fig. 2c). When cmyc-SKA2 was
transfected into HEK cells, both endogenous and transfected
forms of SKA2 were detected (Fig. 2d).
Expression of SKA2 in human lung and breast carcinomas
Immunoﬂuorescencelocalized SKA2 mainly to the cytoplasm
of the NSCLC cell line, A549 (Fig. 3a). Expression of SKA2
was also seen in human SCLC xenografts (Fig. 3b) and in a
resected human lung adenocarcinoma. SKA2 was also
detected in a selection of primary human lung cancers of
different histological types. However, using the more sensitive
immunoperoxidase technique, expression of SKA2 was also
seen in non-tumourous human lung recovered from the
resection margins of surgical specimens (Fig. 4a).
As high-level SKA2 expression was seen in breast cancer cell
lines,expressionwassoughtinabreasttissuearray.Expressionof
SKA2 was easily detected and speciﬁcity was ensured by using
peptide adsorbed controls (Fig. 4b). As with the lung cancer
tissue samples, expression of SKA2 was found in both normal
and cancerous breast (Fig. 4b) with similar expression levels
(mean intensity: 2.5 for cancers and 2.4 for normal; PZ0.67).
However, there was a striking difference in the intracellular
distribution of the SKA2 between normal and tumour tissue,
with a greater proportion of the tumour cells having nuclear
SKA2 when compared with the normal breast (P!0.001).
Intracellular localization of SKA2 and GR in HEK293 cells
AsthedistributionofSKA2withincellsappearedtobedifferent
innormalandtumourcells,westudieditslocalizationinrelation
to that of the GR. We stained for SKA2 expression using our
antibodyinHEK293cellsinfectedwithaGR-eYFP-expressing
retrovirus and analyzed untreated and treated cells by
immunoﬂuorescence. GR was cytoplasmic under basal con-
ditions and both Dex, an agonist, and RU486, an antagonist,
promoted nuclear translocationof the GR, as expected (Fig. 5a
and b). SKA2 was also cytoplasmic under basal conditions,
showingco-localizationwithGR(Fig.5a)However,inligand-
treated cells expressing high levels of transgenic GR, there was
also nuclear translocation of SKA2, further supporting an
interaction between the two proteins (Fig. 5).
Figure 7 Regulation of FAM33A/SKA2. (a) Western blot of SKA2
expression in A549 cells treated with dexamethasone (100 nM),
RU486 (100 nM), PMA (0.1 mM), Staurosporine (20 nM), Forskolin
(1 mM), TSA (HDAC inhibitor) (0.5 mM) and the respective vehicle
controls for 18 h. (b) Western blot showing concentration response
of SKA2 regulation by dexamethasone (Dex). Results are
representative of three separate experiments.
Figure 6 SKA2 effects on glucocorticoid function. (a) HepG2 cells
were transiently transfected with SKA2, a TAT3-luc reporter gene
and a CMV-renilla control plasmid and then treated in triplicate
with a range of concentrations of dexamethasone for 16 h before
harvest, and luciferase assay. Corrected luciferase values were
obtained and expressed relative to the vehicle-treated control.
Statistical analysis used ANOVA followed by Tukey–Kramer post
hoc test, **P!0.01. Results are representative of three experiments.
Expression of exogenous cMyc-SKA2 (18 kDa) is shown in inset
immunoblot.(b) SKA2was stablyoverexpressedinHepG2cellsand
the cells were then transiently transfected with TAT3-luc and treated
with dexamethasone in triplicate as above, **P!0.01. Results are
representative of three experiments. (c) SKA2 protein expression in
wild-type A549 cells (wt), a clone stably expressing the non-
silencing control shRNA (non-silencing control) and two clones
stably expressing the SKA2 shRNA. Clone1 displayed intermediate
expression levels of SKA2 and clone 2 showed low levels of
expression, a-tubulin was used as a loading control. (d) A549 cell
clones expressing clone 2 (low SKA2 expression) or a non-silencing
control was transfected with the TAT3-luciferase reporter construct.
After 24 h, cells were exposed to a range of dexamethasone
concentrations for a further 24 h. Results were normalized against a
renilla control. Graph shows mean of nZ3GS.E.M. and analyzed by
ANOVA followed by Bonferroni post hoc test, ***P!0.001. Results
are representative of two independent transfection experiments. (e)
Effect of dexamethasone (100 nM) on total cell number in A549
cells was assessed after 5 days of growth. Graph shows average of
three separate countsGS.E.M. Treatments compared using t-test,
****P!0.0001, ***PZ0.004. Results are representative of two
separate experiments, and two further experiments were assessed
by MTS.
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The effects of SKA2 on GR function were determined by
expressingSKA2intheSKA2null,HepG2cells.Bothtransient
co-transfection of SKA2 with a reporter gene (Fig. 6a) and
introduction of the reporter to the cells stably overexpressing
SKA2 (Fig. 6b) resulted in potentiation of GC transactivation.
Further examination of the effects of SKA2 on GR function
utilized knockdown of SKA2 by stable expression of shRNA in
A549 cells (which we have shown to express SKA2 protein,
Fig. 2). This generated clones expressing shRNA with either
moderate (clone1) or low (clone 2) residual expression of SKA2
(Fig. 6c). Knockdown of SKA2 (in clone 2) reversed the
GC-stimulated transactivation of the TAT3-luciferase reporter,
when compared with the effect in the non-silencing control
(Fig. 6d).
We also examined the effect of SKA2 on GC regulation of
cell proliferation. Dex (100 nM) inhibited proliferation in
A549 cells by 50%. In clones with moderate (clone 1) and low
(clone 2) expression of SKA2, the effect of Dex was abolished
(Fig. 6e). Importantly, there was no effect of altered SKA2
expression on basal proliferation.
Regulation of SKA2 expression
Analysis of the SKA2 gene locus did not suggest how its
expression was regulated. Therefore, A549 cells were treated
with a panel of agents known to affect cell survival or
proliferation.Weexaminedtheeffectsofthevariouscompounds
on SKA2 protein expression by immunoblot. This revealed
marked inhibition of SKA2 expression by Dex, Staurosporine,
phorbol ester and TSA, all of which either induce apoptosis or
inhibit cell proliferation in A549 cells (Fig. 7).
SKA2 potentiates cell proliferation
To determine the effect of SKA2 on cell proliferation, a non-
expressing cell line, HepG2 (Fig. 2), was transfected with a
SKA2 expression cassette and stable clones were selected
(Fig. 8a). The SKA2-expressing clone had a signiﬁcantly
enhanced proliferative response at 24 h post-IGF-I and a
nearly twofold increase in proliferation at 48 h, compared
with control, but there were no signiﬁcant differences seen
under non-stimulated conditions (Fig. 8b).
Knockdown of SKA2 in A549 cells caused cells to be held
in mitosis (Fig. 8c) as evidenced by the percentage of increase
in mitotic ﬁgures when compared with the non-silencing
control (Fig. 8d).
Gene array proﬁling of SKA2 function
Initial studies identiﬁed speciﬁc siRNA sequences that
potently inhibited SKA2 protein expression. Two separate Figure8 SKA2 affects cell proliferation andmitosis.(a) Westernblot
showing stable expression of cMyc-SKA2 in HepG2 cells. SKA2-
null HepG2 cells were transfected with cMyc-SKA2, clones were
selected using neomycin and screened for cMyc-SKA2 expression
byimmunoblot. Clones 1–4 are presented; clone 1 expressed SKA2.
A, parental HepG2 cells; B, HEK293 cells transiently transfected
with cMyc-SKA2. Migration of the endogenous SKA2 in HEK cells
and the transgenic myc-tagged SKA2 is marked. (b) MTT cell
proliferation assay. Cells from clone 1 and non-expressing clone 4
were serum starved for 24 h before treatment with 5 nM IGF-I in
triplicate. Cells were assayed after both 24 and 48 h. Statistical
analysis used ANOVA followed by Tukey–Kramer post hoc test,
*PZ0.02, ***PZ0.0001. Results are representative of two
experiments. (c) Mitotic ﬁgures. A549 clones expressing shRNA to
SKA2 and non-silencing control were grown overnight on cover-
slips and mounted in DAPI-containing mounting medium; arrows
indicate mitotic cells. (d) Quantiﬁcation of mitotic ﬁgures. The
percentage of cells undergoing mitosis was calculated from a ﬁeld
of 100 cells. Graph shows average of three separate countsGS.E.M;
t-testwasusedwithBonferronicorrectionformultiplecomparisons.
Wild-type compared with clone 2, **PZ0.021; other comparisons
with wild-type were non-signiﬁcant.
Figure 9 Two effective siRNA molecules targeting SKA2 were
identiﬁed and used in microarray analysis to compare the
transcriptional changes between wild-type A549 cells and A549
cells transfected with SKA2 siRNA molecules. Three SKA2-speciﬁc
siRNAs were transiently transfected into cells at the concentrations
shown. Two of the siRNAs showed greater than 80% SKA2
knockdown at 24 h (numbers 3 and 4). These two were used in the
microarray analysis summarized in Table 1.
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post-array analysis (Fig. 9). For post-analysis purposes, a
relatively lenient q value threshold of 0.2 produced 119 probe
sets that were speciﬁcally and signiﬁcantly regulated by both
SKA2-speciﬁc siRNAs. Of these genes, SKA2 was itself
downregulated eightfold.
These genes were analysed for enrichment of Gene
Ontology categories with GennMAPP (Doniger et al.
2003), DAVID (Sherman et al. 2007) and MetaCore
(GeneGo, Inc.) softwares. We found that SKA2 knockdown
in A549 cells resulted in coordinate regulation of a pattern of
genes including gene products known to be involved in cell
cycle, apoptosis and signalling (Table 1).
Discussion
As part of a genetic screen for GR-interacting proteins in
SCLC we identiﬁed SKA2. During our characterization of
SKA2, it was independently discovered as part of a complex
involved in mitosis (Hanisch et al. 2006). SKA2 is required for
assembly of condensed chromosomes on the metaphase plate
(Hanisch et al. 2006). This, in turn, regulates the spindle
checkpoint which on silencing, allows the exit from
metaphase and the onset of anaphase. SKA2 protein requires
SKA1, a protein binding partner, for stability, and SKA2 is
required for correct assembly of SKA1 on the kinetochore.
When cellsweredepleted of SKA proteins therewas a marked
delay in progress through mitosis, implying failure to silence
the spindle checkpoint. This suggests that the SKA proteins
have a role in regulating progression through mitosis.
WefoundSKA2expressionnotonlyinmultiplehumanlung
cancerandbreastcancercelllinesandprimarytumours,butalso
in normal lung and breast tissue. HepG2 cells expressed no
detectable SKA2 protein, demonstrating that high-level SKA2
expression is not a universal feature of transformed cells. Given
thatweandothers(Hanischetal.2006)havefoundSKA2inthe
cytoplasm of interphase cultured cells, it is interesting to note
that there was markedly higher nuclear localization of SKA2 in
breast cancer than normal breast tissue.
Table 1 Genes regulated by SKA2 knockdown involved in cell cycle, apoptosis and signalling (SKA2 result included). Genes found to be
signiﬁcantly up- or downregulated in response to ‘knockdown’ of SKA2 expression by speciﬁc siRNA. Statistical signiﬁcance is indicated
by q value
Entrez gene Probe set ID Fold change q value Gene title
Gene symbol
Downregulated
SKA2 348 235 225684_at K8.70 .044 Family with sequence similarity 33, member A
ABCA1 19 203504_s_at K2.90 .033 ATP-binding cassette, sub-family A (ABC1),
member 1
PPP2R1B 5519 202883_s_at K2.60 .110 Protein phosphatase 2 (formerly 2A), regulatory
subunit A, b isoform
CCL2 6347 216598_s_at K2.50 .143 Chemokine (C-C motif) ligand 2
IL6ST 3572 204863_s_at K2.20 .110 Interleukin 6signaltransducer(gp130,oncostatin
M receptor)
PPP2CA 5515 238719_at K2.10 .148 Protein phosphatase 2 (formerly 2A), catalytic
subunit, a isoform
BMP2K 55 589 226853_at K2.00 .090 BMP2 inducible kinase
EMR1 2015 207111_at K2.00 .185 EGF-like module containing, mucin-like,
hormone receptor-like 1
SOCS3 9021 227697_at K1.90 .198 Suppressor of cytokine signalling 3
LRP12 29 967 220254_at K1.90 .143 Low density lipoprotein-related protein 12
RGS17 26 575 220334_at K1.90 .110 Regulator of G-protein signalling 17
WWTR1 25 937 202132_at K1.60 .159 WW domain containing transcription regulator 1
WWTR1 25 937 202133_at K1.50 .166 WW domain containing transcription regulator 1
Upregulated
NOVA1 4857 205794_s_at 1.50 .185 Neuro-oncological ventral antigen 1
COL4A4 1286 214602_at 1.60 .159 Collagen, type IV, a 4
UNC5D 137 970 231325_at 1.70 .169 Unc-5 homolog D (C. elegans)
IGFBPL1 347 252 227760_at 1.80 .193 IGF-binding protein-like 1
GRB10 2887 209409_at 1.80 .169 Growth factor receptor-bound protein 10
G3BP2 9908 208841_s_at 1.80 .159 GTPase activating protein (SH3 domain) binding
protein 2
PHACTR2 9749 227947_at 1.80 .159 Phosphatase and actin regulator 2
AI831506
(Refseq)
– 226520_at 2.00 .091 PrimaryneuroblastomacDNA, clone:Nbla11485
NOLC1 9221 211951_at 2.20 .088 Nucleolar and coiled-body phosphoprotein 1
CASP7 840 207181_s_at 2.50 .159 Caspase 7, apoptosis-related cysteine peptidase
MESDC2 23 184 224675_at 4.20 .021 Mesoderm development candidate 2
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construct, there was partial SKA2 translocation to the nucleus
following GC treatment. This suggests that there may be
functional interaction between the two proteins in the
cytoplasm and that SKA2, which lacks a nuclear localization
domain, is being ‘drawn’ into the nucleusby the movement of
GR. However, this effect appears to require overexpression of
GR to be seen clearly. This suggests that under particular
conditions, as seen in breast cancer or GR overexpression, the
nuclear exclusion of SKA2 in interphase is lost, with possible
consequences for cell proliferation or survival.
As SKA2 was found to interact with the GR, its effect on
GR transactivation function was sought. Overexpressed
SKA2 resulted in modest enhancement of GR transactivation,
while knockdown of SKA2 markedly inhibited GR
transactivation. This supports a functional interaction
between the two proteins. SKA2 also appears to have a role
in GC inhibition of cell proliferation, in that, knockdown of
SKA2 prevented the decrease in cell number seen with Dex
treatment.
SKA2 protein expression was inhibited by agents that share
anti-proliferative or pro-apoptotic actions on A549 cells. Dex
had profound inhibitory effects on SKA2 expression and
given that GCs are widely used in the induction phase of
anti-cancer chemotherapy, this has implications for cell
cycle control and appropriate chromosomal segregation,
through interference with the spindle checkpoint (Hanisch
et al. 2006).
To explore SKA2 function further, it was overexpressed in
the SKA2 deﬁcient cell line HepG2. This signiﬁcantly
enhanced proliferation following incubation with IGF-I,
which suggests involvement of SKA2 in either growth factor
signalling or cell survival/proliferation pathways. This is
supported by knockdown of SKA2 in A549 cells, which
produced an increase in cells arrested in mitosis as previously
shown for HeLa S3 cells (Hanisch et al. 2006).
Cells were subjected to transcript proﬁling and genes were
identiﬁed where expression was regulated by both SKA2
siRNAs, but not by a non-targeting siRNA. The SKA2
transcript was found in this group of genes to be markedly
repressed, conﬁrming the success of the knockdown approach.
Functional grouping of identiﬁed genes using gene ontology
approaches identiﬁed signiﬁcant enrichment in pathways
regulating cell survival, cell proliferation and also cytokine/
growth factor action, as evidenced by the list of signiﬁcantly
regulated genes clustered in these pathways (Table 1).
To conclude, we have identiﬁed and functionally charac-
terized a novel GR-interacting protein, which we isolated
from a human SCLC cell line. It has recently been identiﬁed
as SKA2, a protein involved in regulating anaphase onset in
HeLa S3 cells. Our studies show that SKA2 is expressed not
only in a range of cell lines but also found in human lung and
breast cancer tissue. In cells overexpressing GR, treatment
with GC causes SKA2 to be co-localized with the GR in the
nucleus. Interestingly, SKA2 is found predominantly in the
nucleus in breast tumours but in the cytoplasm in normal
tissue. The impact of depletion of SKA2 on apoptotic- and
proliferation-associated genes suggests that SKA2 may play a
role in regulation of cancer cell proliferation.
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